Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Daxor Corporation Announces Publication of "Blood Volume Determination, A Nuclear Medicine Test in Evolution"

DXR
Daxor Corporation Announces Publication of "Blood Volume Determination, A Nuclear Medicine Test in Evolution"

http://media.marketwire.com/attachments/200702/315445_Daxorlogoresized.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1033556&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwired) -- 07/11/13 -- Daxor Corporation, (NYSE MKT: DXR) announced today that the July, 2013 issue of the journal Clinical Nuclear Medicine (Vol. 38, #7, p 534-540) has published a review article by Dr. Donald Margouleff, MD, FACP, entitled "Blood Volume Determination, A Nuclear Medicine Test in Evolution". Dr. Margouleff is Board Certified in both Nuclear Medicine and Internal Medicine. He is Chief Emeritus of the Division of Nuclear Medicine Department of Radiology at North Shore University Hospital in Manhasset, New York. He is also a member of the Department of Medicine at the same institution with the academic title of Professor of Clinical Medicine. For over 20 years Dr. Margouleff served as Chairman of the Radiological Health Advisory Committee of the Bureau of Environmental Radiation Protection of the New York State Department of Health. Dr. Margouleff was responsible for introducing the second PET scanner and Cyclotron in New York State, which is used for cancer staging and clinical applications.

The article reviewed the following topics and the utilization of blood volume measurement:

1. The development of an automated system for rapid measurement of blood volume
2. The clinical application of blood volume measurement in the diagnosis of treatment in congestive heart failure
3. The evaluation of kidney failure and its treatment utilizing renal dialysis
4. Syncope (loss of consciousness)
5. Postural Orthostatic Tachycardia Syndrome
6. Hyponatremia
7. Preoperative and Postoperative Screening for Occult (hidden) Anemia
8. Hypertension
9. Shock
10. Increased capillary transudation rate in burn patients

Dr. Feldschuh, President of Daxor, noted that this is the first comprehensive review article on the multiple areas of medicine and surgery where blood volume measurement can significantly improve essential clinical management decisions.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.

Daxor Contact Information:
Richard Dunn
Director of Operations
212-330-8502
rdunn@daxor.com

Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today